PJ34

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    IC50 Value: 20 nM(EC50)[1]
    PJ34 (hydrochloride) is a novel potent specific inhibitor of PARP-l. PJ34 has been reported to enhance chemotherapeutic effects in certain types of tumors.
    in vitro: PJ34 inhibited peroxynitrite-induced cell necrosis with EC50 of 20 nM. PJ34 provides cardioprotection by decreasing myocardial infarct size and enhancing postischemic regional and global functional recovery [1]. Treatment with PJ34 increased NIS promoter activity without affecting PARP-1 binding to the promoter sequence, in addition to an increase of histone modification activation marks (H3K9K14ac, H3K4me3) [2].
    in vivo: In a model of systemic endotoxemia, PJ34 pretreatment significantly reduced plasma levels of TNF-alpha, IL-1beta and nitrite/nitrate (breakdown products of nitric oxide) production. PJ34 treatment (oral gavage) induced a significant suppression of the inflammatory response in dextran sulfate colitis, multiple low dose streptozotocin diabetes [3]. The PJ34 showed significant reduction on infarct size (37.5%+/-4.5% and 50.5%+/-4.8% of the area at risk) for PJ34 and control pigs groups, respectively, (p < 0.05) [4].
    Clinical trial: N/A
- Properties
  - Alternative Name
    
    PJ-34;PJ 34; 2-(dimethylamino)-N-(6-oxo-5H-phenanthridin-2-yl)acetamide
    
    CAS Number
    
    344458-19-1
    
    Molecular Formula
    
    C17H17N3O2
    
    Molecular Weight
    
    295.34
    
    Purity
    
    95.69%
    
    Solubility
    
    Soluble in DMSO
    
    Storage
    
    Store at -20°C
    
    * For Research Use Only

PJ34

Background

We Also Recommend

PND-1186

Poloxin

Pramipexole dihydrochloride